Peruse (MO28047)
|
P + T + Tx
|
mBC HER 2+
|
1436
|
Multicenter clinical practice, single-arm phase IV study to evaluate the safety of the combination in real life world
|
Pertain (MO27775)
|
P + T + AI vs T + AI
|
mBC HER2+ HR+ Post menopausal status
|
250
|
Randomized multicenter open label phase II study designed to assess the efficacy and safety of P+ T + AI [anastrozole or letrozole) or T+ AI. Pts in either arm may also receive induction chemotherapy for up to 18 weeks at the investigator’s discretion.
|
Velvet (MO27782)
|
P + T + VNR
|
mBC HER2+
|
210
|
Randomized, multicenter open-label, single-arm with 2 cohorts of patients (cohort 1 = sequential infusion of P and T; cohort 2 concomitant P and T) designed to evaluate the efficacy and safety of P in combination with VNR
|
Metapher (BO29159)
|
P + T (s.c) + Tx
|
mBC HER2+
|
400
|
Multicenter single-arm phase IIIb study, designed to evaluate the safety and efficacy of the combination P + T subcutaneously + Tx
|